ABCL vs. VRNA, MNKD, ELVN, COLL, MIRM, PCRX, SYRE, BLTE, PRTA, and GYRE
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Verona Pharma (VRNA), MannKind (MNKD), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Belite Bio (BLTE), Prothena (PRTA), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical preparations" industry.
AbCellera Biologics (NASDAQ:ABCL) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
AbCellera Biologics presently has a consensus price target of $16.17, suggesting a potential upside of 322.11%. Verona Pharma has a consensus price target of $33.60, suggesting a potential upside of 126.26%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Verona Pharma.
In the previous week, AbCellera Biologics had 12 more articles in the media than Verona Pharma. MarketBeat recorded 23 mentions for AbCellera Biologics and 11 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.42 beat AbCellera Biologics' score of 0.18 indicating that Verona Pharma is being referred to more favorably in the news media.
Verona Pharma received 259 more outperform votes than AbCellera Biologics when rated by MarketBeat users. Likewise, 79.90% of users gave Verona Pharma an outperform vote while only 77.27% of users gave AbCellera Biologics an outperform vote.
AbCellera Biologics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.
Verona Pharma has lower revenue, but higher earnings than AbCellera Biologics. Verona Pharma is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Verona Pharma has a net margin of 0.00% compared to AbCellera Biologics' net margin of -410.47%. AbCellera Biologics' return on equity of -12.61% beat Verona Pharma's return on equity.
Summary
AbCellera Biologics beats Verona Pharma on 9 of the 17 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
